Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520854 | 0.84 | DYRK1A (0.60) | MAPTHSD17B10FGFR1GRM5SMN1; SMN2 | |
| Butyric Acid SCHEMBL28021104 | 0.82 | MAPT (0.48) | MAPTHSD17B10FGFR1GRM5SMN1; SMN2 | |
| SCHEMBL24569506 | 0.81 | FGFR1 (0.54) | MAPTHSD17B10FGFR1GRM5SMN1; SMN2 | |
| SCHEMBL28548121 | 0.81 | MAPT (0.47) | MAPTHSD17B10FGFR1GRM5SMN1; SMN2 | |
| SCHEMBL24569955 | 0.78 | NPC1 (0.45) | MAPTHSD17B10FGFR1GRM5SMN1; SMN2 | |
| SCHEMBL1191996 | 0.78 | KMT2A (0.46) | MAPTHSD17B10FGFR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL434799 | 0.78 | NPC1 (0.58) | MAPTHSD17B10FGFR1GRM5SMN1; SMN2 | |
| SCHEMBL19911410 | 0.78 | MAPT (0.58) | MAPTHSD17B10FGFR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19911395 | 0.77 | MAPT (0.53) | MAPTHSD17B10FGFR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL23750358 | 0.77 | KMT2A (0.43) | MAPTHSD17B10FGFR1GRM5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4511375-A1 | BICYCLIC COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2024254490-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | ACRIVON THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024249817-A1 | TRICYCLIC PKMYT1 KINASE INHIBITORS | ENLIVEN INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-119053599-A | Bicyclic compounds | 安力高医药股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240287003-A1 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | UNIVERSITE EUROMEDITERRANEENNE DE FES (MA) | 2024-08-29 | — | — | US | disclosed |
| CN-114901664-B | Pyridone compounds and uses thereof | 南京再明医药有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-117903110-A | HBV inhibitors and uses thereof | 西安新通药物研究股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-1217000-A1 | Inhibitors of factor Xa and factor VIIa | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| US-20020072536-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-13 | — | — | US | disclosed |
| US-6403626-B1 | USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020065307-A1 | Novel benzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-05-30 | — | — | US | disclosed |
| US-6316637-B1 | SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6043254-A | ANTIPROLIFERATIVE AGENT; ENZYME INHIBITOR | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-03-28 | — | — | US | disclosed |
| EP-0775134-A4 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMA CORP (US) | 1997-08-13 | — | — | EP | disclosed |
| EP-0775134-A1 | Imidazolin-2-ylaminobenzimidazole derivatives | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004270-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-02-15 | — | — | WO | disclosed |
| US-4460709-A | Process for producing oxygen-containing organic compounds | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1984-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065307-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | MAPT 4094/4885HSD17B10 1553/4885FGFR1 1521/4885 |
| US-20020072536-A1 | Novel benzimidazole derivatives | OPRD1, OPRL1, OPRM1 | MAPT 4095/4885HSD17B10 1553/4885FGFR1 1596/4885 |
| US-20240287003-A1 | ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION | ACE2, ACE, TMPRSS2 | MAPT 3905/4885HSD17B10 913/4885FGFR1 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.